Thank You for Requesting Our Media Kit

Media Kit Thank You2023-08-07T18:46:39-04:00

US FDA Approves Kloxxado® (naloxone HCl) Nasal Spray 8 mg to Treat Opioid Overdose

Hikma Pharmaceuticals announced, on April 30, 2021, the US Food and Drug Administration (FDA) approval of Kloxxado® (naloxone HCl) Nasal Spray 8 mg, a new opioid overdose reversal medication.

young mixed race woman looking at a laptop

Frequently Asked Questions

Learn more about Kloxxado® by exploring common patient and caregiver questions.

Go to Top

Important Safety Information About KLOXXADO® (naloxone HCl) Nasal Spray 8 mg